Land: Kanada
Sprache: Englisch
Quelle: Health Canada
ERLOTINIB (ERLOTINIB HYDROCHLORIDE)
NATCO PHARMA (CANADA) INC
L01EB02
ERLOTINIB
150MG
TABLET
ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 150MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0151203003; AHFS:
APPROVED
2018-12-14
PRODUCT MONOGRAPH PR NAT-ERLOTINIB Erlotinib hydrochloride tablets 25 mg, 100 mg and 150 mg erlotinib Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Protein Kinase Inhibitor (L01XE03) Natco Pharma (Canada) Inc. 2000 Argentia Road, Plaza 1, Suite 200 Mississauga, Ontario, Canada L5N 1P7 Date of Revision: July15, 2020 SUBMISSION CONTROL NO: 238581 _Page 2 of 48_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS .................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................. 4 ADVERSE REACTIONS .................................................................................................... 9 DRUG INTERACTIONS .................................................................................................. 16 DOSAGE AND ADMINISTRATION .............................................................................. 18 OVERDOSAGE ................................................................................................................. 20 ACTION AND CLINICAL PHARMACOLOGY ............................................................. 20 STORAGE AND STABILITY .......................................................................................... 22 SPECIAL HANDLING INSTRUCTIONS ........................................................................ 22 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................. 23 PART II: SCIENTIFIC INFORMATION ............................................................................... 24 PHARMACEUTICAL INFORMATION .......................................................................... Lesen Sie das vollständige Dokument